Agios Pharmaceuticals (NASDAQ: AGIO) has recently been the focus of several updates from research analysts regarding its ratings and price targets. This comes as insider trading activity reveals significant stock transactions by company executives.
On October 27, 2023, insider Sarah Gheuens sold 3,302 shares of Agios Pharmaceuticals at an average price of $43.92 per share. This transaction totaled approximately $145,023.84. After the sale, Gheuens retains ownership of 61,727 shares, valued at around $2,711,049.84, marking a decrease of 5.08% in her position. The details of this trade were disclosed in a filing with the Securities & Exchange Commission.
In a separate transaction, Chief Financial Officer Cecilia Jones sold 3,651 shares on September 26, 2023, at an average price of $36.77. The total value of this sale amounted to $134,247.27. Following this transaction, Jones holds 33,870 shares, valued at approximately $1,245,399.90, representing a 9.73% reduction in her ownership. This transaction was also reported to the SEC.
Over the past three months, insiders at Agios Pharmaceuticals have sold a total of 7,553 shares, valued at $305,001. Currently, insiders hold 4.30% of the company’s stock.
Agios Pharmaceuticals, based in the United States, is a biopharmaceutical company that specializes in the discovery and development of medicines targeting cellular metabolism. Its flagship product, PYRUKYND (mitapivat), acts as an activator for wild-type and mutant pyruvate kinase (PK) enzymes, aimed at treating hemolytic anemias.
As analysts continue to adjust their ratings and price targets, stakeholders will be keen to monitor these developments closely. For those interested in ongoing updates about Agios Pharmaceuticals and related companies, resources are available for daily summaries of news and analyst ratings.
